NEW YORK (GenomeWeb) – Biodesix said today that it has added $12 million in follow-on financing to a series E round that raised $15 million in 2013 and 2014, bringing total proceeds of the sale to $27 million.
The company said that existing shareholders provided nearly all of the capital for the follow-on sale.
Biodesix will use the investment to continue development of its blood-based molecular diagnostic technology platform and test menu. It will also support the commercialization efforts of the company's VeriStrat serum protein test, which helps physicians select the appropriate therapy for patients with advanced non-small cell lung cancer.